Anidulafungin
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Anidulafungin |
| DrugBank ID | DB00362 |
| Brand Names (EU) | Ecalta |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.85% |
Approved Indication (EMA)
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | impetigo | 98.85% | DL |
| 2 | malignant pleural mesothelioma | 98.75% | DL |
| 3 | staphylococcal scalded skin syndrome | 98.73% | DL |
| 4 | pleural empyema (disease) | 98.52% | DL |
| 5 | malignant visceral pleura tumor | 98.45% | DL |
| 6 | bullous impetigo | 98.40% | DL |
| 7 | malignant epithelioid mesothelioma | 98.37% | DL |
| 8 | sarcomatoid mesothelioma | 98.26% | DL |
| 9 | hordeolum | 98.23% | DL |
| 10 | Clostridium infectious disease | 98.22% | DL |
| 11 | pleural neoplasm | 98.08% | DL |
| 12 | inhalational botulism | 97.65% | DL |
| 13 | toxin-mediated infectious botulism | 97.64% | DL |
| 14 | cysticercosis | 97.34% | DL |
| 15 | staphylococcal pneumonia | 97.02% | DL |
| 16 | coenurosis | 96.89% | DL |
| 17 | lymph node palisaded myofibroblastoma | 96.86% | DL |
| 18 | abdominal cystic lymphangioma | 96.86% | DL |
| 19 | celiac trunk compression syndrome | 96.86% | DL |
| 20 | abdominal ectopic pregnancy | 96.86% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.